"Carcinoma, Renal Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
Descriptor ID |
D002292
|
MeSH Number(s) |
C04.557.470.200.025.390 C04.588.945.947.535.160 C12.758.820.750.160 C12.777.419.473.160 C13.351.937.820.535.160 C13.351.968.419.473.160
|
Concept/Terms |
Carcinoma, Renal Cell- Carcinoma, Renal Cell
- Carcinomas, Renal Cell
- Renal Cell Carcinomas
- Adenocarcinoma, Renal Cell
- Adenocarcinomas, Renal Cell
- Renal Cell Adenocarcinoma
- Renal Cell Adenocarcinomas
- Adenocarcinoma Of Kidney
- Adenocarcinoma Of Kidneys
- Kidney, Adenocarcinoma Of
- Kidneys, Adenocarcinoma Of
- Renal Cell Cancer
- Cancer, Renal Cell
- Cancers, Renal Cell
- Renal Cell Cancers
- Adenocarcinoma, Renal
- Adenocarcinomas, Renal
- Renal Adenocarcinoma
- Renal Adenocarcinomas
- Nephroid Carcinoma
- Carcinoma, Nephroid
- Carcinomas, Nephroid
- Nephroid Carcinomas
- Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma- Clear Cell Renal Cell Carcinoma
- Grawitz Tumor
- Tumor, Grawitz
- Clear Cell Renal Carcinoma
- Carcinoma, Hypernephroid
- Carcinomas, Hypernephroid
- Hypernephroid Carcinoma
- Hypernephroid Carcinomas
- Hypernephroma
- Hypernephromas
Collecting Duct Carcinoma (Kidney)- Collecting Duct Carcinoma (Kidney)
- Carcinoma, Collecting Duct (Kidney)
- Carcinomas, Collecting Duct (Kidney)
- Collecting Duct Carcinomas (Kidney)
- Collecting Duct Carcinoma of the Kidney
- Renal Collecting Duct Carcinoma
- Collecting Duct Carcinoma
- Carcinoma, Collecting Duct
- Carcinomas, Collecting Duct
- Collecting Duct Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Renal Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Renal Cell".
This graph shows the total number of publications written about "Carcinoma, Renal Cell" by people in this website by year, and whether "Carcinoma, Renal Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 9 | 1 | 10 |
1995 | 12 | 2 | 14 |
1996 | 13 | 1 | 14 |
1997 | 14 | 2 | 16 |
1998 | 9 | 1 | 10 |
1999 | 9 | 0 | 9 |
2000 | 3 | 4 | 7 |
2001 | 11 | 2 | 13 |
2002 | 16 | 3 | 19 |
2003 | 28 | 7 | 35 |
2004 | 19 | 2 | 21 |
2005 | 22 | 3 | 25 |
2006 | 28 | 3 | 31 |
2007 | 38 | 2 | 40 |
2008 | 43 | 7 | 50 |
2009 | 37 | 6 | 43 |
2010 | 51 | 5 | 56 |
2011 | 59 | 5 | 64 |
2012 | 49 | 4 | 53 |
2013 | 50 | 4 | 54 |
2014 | 61 | 6 | 67 |
2015 | 66 | 2 | 68 |
2016 | 42 | 5 | 47 |
2017 | 59 | 0 | 59 |
2018 | 42 | 2 | 44 |
2019 | 33 | 1 | 34 |
2020 | 43 | 4 | 47 |
2021 | 48 | 0 | 48 |
2022 | 26 | 0 | 26 |
2023 | 33 | 0 | 33 |
2024 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Renal Cell" by people in Profiles.
-
YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
-
ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97. Nat Commun. 2024 Feb 07; 15(1):1165.
-
Locoregional Therapies in Immunologically "Cold" Tumors: Opportunities and Clinical Trial Design Considerations. J Vasc Interv Radiol. 2024 Feb; 35(2):198-202.
-
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nat Commun. 2024 Feb 01; 15(1):972.
-
NCCN Guidelines? Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024 02; 22(1):4-16.
-
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. Oncoimmunology. 2024; 13(1):2290787.
-
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Res. 2023 12 15; 83(24):4161-4178.
-
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2024 Jan; 196:113434.
-
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review. Cancer Treat Rev. 2024 Jan; 122:102652.
-
Racial Disparities in MiT Family Translocation Renal Cell Carcinoma. Oncologist. 2023 Nov 02; 28(11):1009-1013.